Zdrowie i gospodarka · 08/07/2014

Patient-Focused Drug Development for Idiopathic Pulmonary Fibrosis; Public Meeting; Request for Comments

The Food and Drug Administration (FDA) is hosting a public meeting to gather patient perspectives on idiopathic pulmonary fibrosis and treatment approaches, as part of its performance commitments under the Prescription Drug User Fee Act (PDUFA V). The public is invited to provide comments on the topic.